HOOK vs. GRTS, NTGN, ALDX, EPIX, TSVT, PYXS, ME, TRVI, ABEO, and STTK
Should you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Gritstone bio (GRTS), Neon Therapeutics (NTGN), Aldeyra Therapeutics (ALDX), ESSA Pharma (EPIX), 2seventy bio (TSVT), Pyxis Oncology (PYXS), 23andMe (ME), Trevi Therapeutics (TRVI), Abeona Therapeutics (ABEO), and Shattuck Labs (STTK). These companies are all part of the "medical" sector.
Gritstone bio (NASDAQ:GRTS) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, community ranking, risk and analyst recommendations.
48.5% of Gritstone bio shares are held by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are held by institutional investors. 4.6% of Gritstone bio shares are held by company insiders. Comparatively, 3.3% of Hookipa Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Hookipa Pharma has a net margin of -88.73% compared to Hookipa Pharma's net margin of -926.13%. Gritstone bio's return on equity of -33.33% beat Hookipa Pharma's return on equity.
Gritstone bio received 54 more outperform votes than Hookipa Pharma when rated by MarketBeat users. However, 69.84% of users gave Hookipa Pharma an outperform vote while only 69.61% of users gave Gritstone bio an outperform vote.
Hookipa Pharma has higher revenue and earnings than Gritstone bio. Hookipa Pharma is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Gritstone bio had 8 more articles in the media than Hookipa Pharma. MarketBeat recorded 19 mentions for Gritstone bio and 11 mentions for Hookipa Pharma. Gritstone bio's average media sentiment score of 0.46 beat Hookipa Pharma's score of 0.05 indicating that Hookipa Pharma is being referred to more favorably in the news media.
Gritstone bio currently has a consensus target price of $4.75, indicating a potential upside of 627.97%. Hookipa Pharma has a consensus target price of $43.25, indicating a potential upside of 603.25%. Given Hookipa Pharma's higher possible upside, research analysts clearly believe Gritstone bio is more favorable than Hookipa Pharma.
Gritstone bio has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
Summary
Hookipa Pharma beats Gritstone bio on 9 of the 16 factors compared between the two stocks.
Get Hookipa Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hookipa Pharma Competitors List
Related Companies and Tools
Free HOOK Stock Alerts